8-K: iRhythm Posts Record Q4, First GAAP Net Income in History

iRhythm Holdings, Inc. reported strong fourth quarter and full year 2025 financial results, achieving record revenue and its first-ever quarter of positive GAAP net income.

Summary

• Fourth quarter 2025 revenue increased 27.1% to $208.9 million, marking a record quarter and the fifth consecutive quarter of over 20% year-over-year growth.
• The company achieved its first quarter of positive GAAP net income in its history, reaching $5.6 million in Q4 2025, a $6.9 million improvement from Q4 2024.
• Full year 2025 revenue grew 26.2% to $747.1 million, driven by increased volume of Zio Services across US core business, innovative health channels, and international markets.
• Gross margin expanded to 70.9% in Q4 2025 (up 90 basis points) and 70.6% for the full year 2025 (up 170 basis points), primarily due to scale, manufacturing efficiencies, and favorable pricing and mix.
• Adjusted EBITDA for Q4 2025 was $34.3 million (16.4% margin), a $15.0 million improvement, and for the full year 2025 was $68.9 million (9.2% margin), a $76.7 million improvement.
• iRhythm generated positive free cash flow of $34.5 million for the full year 2025, marking the first year of positive free cash flow in company history.
• Unrestricted cash, cash equivalents, and marketable securities stood at $583.8 million as of December 31, 2025, an increase of $18.6 million from September 30, 2025.
• For the full year 2026, iRhythm expects revenue between $870 million and $880 million and an adjusted EBITDA margin of 11.5% to 12.5%.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this filing as highly positive, reflecting strong financial performance, significant operational milestones such as the first GAAP net income and positive free cash flow, and a confident outlook for continued growth and profitability.

Positives

• Record quarterly revenue of $208.9 million in Q4 2025, a 27.1% increase year-over-year.
• Achieved first quarter of positive GAAP net income in company history, with $5.6 million in Q4 2025.
• Gross margin improved by 90 basis points to 70.9% in Q4 2025 and by 170 basis points to 70.6% for the full year 2025.
• Adjusted EBITDA significantly improved to $34.3 million (16.4% margin) in Q4 2025 and $68.9 million (9.2% margin) for the full year 2025.
• Generated positive free cash flow of $34.5 million for the full year 2025, a first for the company.
• Strong cash position with $583.8 million in unrestricted cash, cash equivalents, and marketable securities at year-end 2025.
• Fifth consecutive quarter of revenue growth above 20% year-over-year, indicating sustained business momentum.
• Increased demand for Zio services across cardiology, primary care, and innovative channel partnerships.

Negatives

• Despite significant improvement, the company reported a net loss of $44.6 million for the full year 2025.

Risks

• The filing refers to risks described in the section entitled Risk Factors and elsewhere in the company's filings made with the Securities and Exchange Commission, including those on the Form 10-K expected to be filed on or about February 19, 2026, rather than detailing specific new risks within this report.

Future Outlook

iRhythm expects continued strong performance in 2026, projecting revenue between $870 million and $880 million and an adjusted EBITDA margin of 11.5% to 12.5%. This guidance reflects anticipated volume-led growth, further gross margin expansion, and operating leverage, while maintaining disciplined investment in innovation and market expansion.

Management Comments

• "The fourth quarter capped a transformational year for iRhythm."
• "In 2025, we delivered strong revenue growth, meaningfully expanded margins, and achieved positive quarterly GAAP net income for the first time in our history — milestones that reflect both the strength of our execution and the durability of our business model."
• "Demand for Zio continues to broaden across cardiology, primary care, and innovative channel partnerships as health systems and payers increasingly recognize the value of proactive, data-driven arrhythmia detection."
• "As health systems and payers increasingly focus on reducing avoidable acute care utilization, the growing body of real-world evidence supporting Zio’s ability to enable earlier diagnosis and more efficient care delivery continues to differentiate our platform."
• "As we enter 2026, our priorities remain consistent: scale our platform globally, advance our next-generation product roadmap, deepen our predictive AI capabilities, and execute with financial discipline to drive sustained, long-term value for patients, physicians, providers, and shareholders."

Industry Context

StockSavvy.ai notes that iRhythm's strong performance underscores the growing demand for digital health solutions, particularly in proactive disease detection and prevention. The company's Zio platform, with its focus on data-driven arrhythmia detection and ability to reduce acute care utilization, aligns well with broader industry trends towards value-based care and efficiency in healthcare delivery. The expansion into primary care and international markets indicates a successful strategy to capture a larger share of the cardiac monitoring market, leveraging technology to address critical healthcare needs.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, achievement of profitability milestones, and positive future guidance, suggesting increased shareholder value.
• Patients: Positive impact through continued innovation and global scaling of Zio services, leading to better arrhythmia detection and prevention.
• Physicians and Providers: Positive impact as the Zio platform offers better data and insights, enabling earlier diagnosis and more efficient care delivery, aligning with their focus on reducing avoidable acute care utilization.
• Employees: Positive impact from a growing and financially healthier company, potentially leading to increased opportunities and stability.

Next Steps

• Present data at the American College of Cardiology's Annual Scientific Session & Expo in New Orleans, Louisiana, from March 28-30, 2026.
• Scale the Zio platform globally.
• Advance the next-generation product roadmap.
• Deepen predictive AI capabilities.
• Execute with financial discipline to drive sustained, long-term value.

Key Dates

Recommendation

The filing presents exceptionally strong financial results, including record revenue, the company's first-ever positive GAAP net income, and its first year of positive free cash flow. These achievements, coupled with robust gross margin expansion and a positive 2026 guidance, demonstrate strong execution and a durable business model. The company's strategic focus on global scaling, product innovation, and AI capabilities further supports long-term growth potential, making it a compelling 'strong buy' for seasoned investors.

Keywords

iRhythm, IRTC, digital health, Zio, arrhythmia detection, wearable biosensors, cardiology, financial results, Q4 2025, full year 2025, adjusted EBITDA, free cash flow, revenue growth, gross margin